Y-mAbs Therapeutics, Inc. Company profile
About Y-mAbs Therapeutics Inc
Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody based therapeutic products for the treatment of cancer. Its product pipeline includes DANYELZA (naxitamab-gqgk), which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor, or GM-CSF,for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Y-mAbs Therapeutics Inc revenues increased 68% to $34.9M. Net loss decreased 54% to $55.3M. Revenues reflect License revenue increase of 59% to $32.9M. Lower net loss reflects Foreign Exchange Gain/LossNon-Business increase from $576K (expense) to $1.9M (income), Licensing royalties decrease of 90% to $210K (expense), Research and development - Balancing val decrease of 2% to $83.5M (expense).
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)